News Search Results
May 06, 2026, 23:29 ET Nona Biosciences Appoints Dr. Josh Xiao as Chief Scientific Officer to Advance Global Scientific Strategy and Innovation
CAMBRIDGE, Mass., May 6, 2026 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, today announced the appointment of Dr. Josh Xiao as Chief Scientific
More news about: Nona Biosciences
May 06, 2026, 17:11 ET /C O R R E C T I O N -- Mana.bio/
(ASGCT)TEL AVIV, Israel and BOSTON, May 6, 2026 /PRNewswire/ -- Mana.bio, a biotechnology company revolutionizing targeted RNA delivery through AI-enabled lipid nanoparticle (LNP) discovery and optimization, today announced the addition
More news about: Mana.bio
May 06, 2026, 16:58 ET TerraPower Isotopes Breaks Ground on World's Largest Actinium-225 Manufacturing Facility in Philadelphia
state-of-the-art manufacturing facility will produce actinium-225 at a scale the industry has never seen before, providing global pharmaceutical and biotechnology companies with the reliable, large-volume supply they need to advance their clinical programs and ultimately expand cancer treatment options for
More news about: TerraPower Isotopes
May 06, 2026, 16:26 ET IMMP Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Immutep Limited
acquired Immutep Limited American Depository Receipts (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026. Immutep is an Australian-based biotechnology company focused on developing Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases. The company's product
More news about: Robbins LLP
May 06, 2026, 16:01 ET Innocan Pharma LPT-CBD is featured in Pain Medicine News
Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries is pleased to announce that its novel Liposomal Delivery Platform for Synthetic Cannabidiol (LPT-CBD) was featured in the Pain Medicine
More news about: Innocan Pharma Corporation
May 06, 2026, 16:01 ET Innocan Pharma LPT-CBD is featured in Pain Medicine News
Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries is pleased to announce that its novel Liposomal Delivery Platform for Synthetic Cannabidiol (LPT-CBD) was featured in the Pain Medicine
More news about: Innocan Pharma Corporation
May 06, 2026, 10:30 ET Image Analysis Group (IAG) and HeartcoR Solutions Announce Strategic Partnership to Deliver Integrated Cardiac Safety and Imaging Core Lab Services for Clinical Trials
Schaumburg, IL, today announced a strategic partnership to deliver fully integrated cardiac safety monitoring and imaging services to pharmaceutical and biotechnology sponsors worldwide.
More news about: HeartcoR Solutions
May 06, 2026, 10:15 ET Life Science Instrumentation Market worth $92.53 billion by 2031 | MarketsandMarkets™
pharmaceutical & biotechnology companies segment accounted for the largest share of the life science instrumentation market in 2025.The life science instrumentation market is segmented into hospitals & diagnostic laboratories, pharmaceutical & biotechnology companies, academic &
More news about: MarketsandMarkets
May 06, 2026, 09:29 ET Partner Therapeutics Announces Receipt of FDA Commissioner's National Priority Voucher for BIZENGRI® (Zenocutuzumab-zbco) in NRG1 Fusion-Positive Cholangiocarcinoma
LEXINGTON, Mass., May 6, 2026 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has awarded a Commissioner's National Priority Voucher (CNPV) pilot program
More news about: Partner Therapeutics, Inc.
May 06, 2026, 09:00 ET Diakonos Oncology Awarded Fast Track Designation by FDA for DOC1021 (dubodencel) in Unresectable or Metastatic Cutaneous Melanoma
Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, announced today that the U.S. Food and Drug
More news about: Diakonos Oncology
May 06, 2026, 09:00 ET Levi & Korsinsky Reminds Regencell Bioscience Holdings Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of June 23, 2026 - RGC
on June 17, 2025, representing a 48,650% increase. The Wall Street Journal noted in January 2026 that only 20 of the 261 companies in the Nasdaq Biotechnology Index had a greater market value than Regencell.Alleged Operational Disconnects by the NumbersRegencell's
More news about: Levi & Korsinsky, LLP
May 06, 2026, 09:00 ET Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
May 06, 2026, 08:52 ET Gallant Advances Canine Osteoarthritis IV-Delivered Stem Cell Therapy with Promising Pilot Data and Expanded FDA Conditional Approval Pathway Eligibility
UMSCsSAN DIEGO, May 6, 2026 /PRNewswire/ -- Gallant, an animal health biotechnology company pioneering off-the-shelf mesenchymal stromal cell (MSC) therapies for pets, today announced that its canine osteoarthritis (OA) MSC therapy
More news about: Gallant
May 06, 2026, 08:00 ET OpenProtein.AI Selected to Build Next-Generation Protein Foundation Models Under DARPA Program
thermodynamic stability."These capabilities will directly advance OpenProtein.AI's commercial platform, which serves pharmaceutical and biotechnology companies applying AI to design-build-test cycles for antibodies, enzymes, and other proteins. The technology also has significant implications
More news about: OpenProtein.AI
May 06, 2026, 08:00 ET Blue Water Acquisition Corp. IV Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing May 11, 2026
business, industry, sector or geographical location, the Company intends to focus on high-potential companies in the artificial intelligence (AI), biotechnology, healthcare and technology sectors.Forward-Looking StatementsThis press release contains statements that constitute "forward-looking
More news about: Blue Water Acquisition Corp. IV
May 06, 2026, 08:00 ET Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen
More news about: Halozyme Therapeutics, Inc.
May 06, 2026, 07:05 ET REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy
of the webcast will be available for approximately 30 days following the presentation.ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
May 06, 2026, 07:00 ET Cytora Ltd. Appoints Dr. Thomas Serena, MD, World‑Renowned Wound Care Expert to Scientific Advisory Board to Lead Patient Treatment Access and Data Collection for CytoraStem™ human Oral Mucosa Stem Cell (hOMSC) Therapy
TEL AVIV, Israel, May 6, 2026 /PRNewswire/ -- Cytora Ltd. ("Cytora"), a clinical-stage biotechnology company developing allogeneic stem cell therapies, today announced the appointment of
More news about: Cytora
May 06, 2026, 06:30 ET Bio-Techne Declares Dividend
company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories. For more information on Bio-Techne and its brands, please visit
More news about: Bio-Techne Corporation
May 06, 2026, 06:30 ET Bio-Techne Releases Third Quarter Fiscal 2026 Results
company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories. For more information on Bio-Techne and its brands, please visit
More news about: Bio-Techne Corporation
May 06, 2026, 06:00 ET NKF Honors Vertex with 2026 Kidney Biotech Innovation Award
medicines for patients with kidney disease who are waiting."The National Kidney Foundation Kidney Biotech Innovation Award recognizes pioneering biotechnology companies that are advancing novel therapies, technologies, or platforms with the potential to significantly improve the prevention, diagnosis,
More news about: National Kidney Foundation
May 06, 2026, 00:40 ET Korea International Trade Association and Korea Development Bank to Host Asia's Largest Startup Fair, "NextRise 2026, Seoul"
is set to be the largest in the event's history. Exhibition booths will feature startups and 23 global companies and institutions spanning AI, biotechnology, and other advanced industries. More than 150 large and mid-sized corporations, including LG Group, Hyundai Motor, SK Telecom, Korean Air, and Renault,
More news about: Korea International Trade Association
May 06, 2026, 00:30 ET Yashraj Bharati Samman: A Tribute to Service, Compassion, and Quiet Impact
hard work contributes to drive enduring, positive change.Dinesh Kumar Jain, Chair of Advisory Board and Managing Director at Yashraj Biotechnology Ltd, said, "The Yashraj Bharati Samman is a tribute to individuals and institutions who work selflessly at the grassroots, often without recognition,
More news about: Yashraj Research Foundation
May 05, 2026, 21:30 ET Nona Biosciences Evolves Brand to Reflect Next Phase of Growth in Biotherapeutic Innovation
CAMBRIDGE, Mass., May 5, 2026 /PRNewswire/ -- Nona Biosciences, a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, announced the launch of its
More news about: Nona Biosciences
May 05, 2026, 20:28 ET MingMed Biotechnology、ARVO（Association for Research in Vision and Ophthalmology）2026において、中等度加齢黄斑変性（AMD）治療薬「QA102」の経口投与に関する良好な第II相データを発表
広州（中国）、2026年5月6日 /PRNewswire/ -- 複数の治療分野における新規治療薬の発見と開発に注力するバイオメディカル企業であるMingMed Biotechnology Co., Ltd.は、中等度ドライ型加齢黄斑変性（AMD）患者を対象としたQA102の第II相臨床試験で良好な結果が得られたと発表しました。この研究結果は、コロラド州デンバーで開催されたARVO（Association for Research in Vision and Ophthalmology）2026年年次総会で口頭発表されました。 中等度ドライAMDは、大きなドルーゼンと色素変化を特徴とする慢性進行性網膜疾患であり、進行性AMDに移行する重大なリスクであります。高齢者における不可逆的失明の最も一般的な原因の一つとして
More news about: MingMed Biotechnology Co., Ltd